AstraZeneca's Farxiga reduced the risk of hospitalisation and death in people with all types of heart failure in the DELIVER trial, which could dramatically increase the population of patients ...

Farxiga (dapagliflozin) and Jardiance (empagliflozin) are prescription medications that are commonly used for type 2 diabetes ...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabetes.